All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
Parkinson’s Institute R. Jeremy Nichols Basic Biology III Understanding the role of LRRK2 in iPSC cell models of Parkinson’s Disease $1,482,822
Scripps Research Institute Dr. Kristin K Baldwin Dr. Basic Biology III Identifying sources of mutation in human induced pluripotent stem cells by whole genome sequencing $1,705,500
University of California, Berkeley Dr. Michael P. Rapé Dr. Basic Biology III Ubiquitin-dependent control of hESC self-renewal and expansion $1,224,805
University of California, Los Angeles Dr. Gay Miriam Crooks Basic Biology III Forming the Hematopoietic Niche from Human Pluripotent Stem Cells $1,252,857
University of California, San Diego Dr. Charles C. King Dr. Basic Biology III Biological relevance of microRNAs in hESC differentiation to endocrine pancreas $1,313,649
University of California, Berkeley Dr. Song Li Basic Biology III Induced Pluripotent Stem Cells for Tissue Regeneration $1,209,148
University of California, San Diego Karl H. Willert Tools and Technologies II Homologous recombination in human pluripotent stem cells using adeno-associated virus. $1,659,043
Stanford University Dr. Marius Wernig MD, PhD Tools and Technologies II Cellular tools to study brain diseases affecting synaptic transmission $1,664,382
Stanford University Professor Irving L Weissman MD Tools and Technologies II Antibody tools to deplete or isolate teratogenic, cardiac, and blood stem cells from hESCs $1,463,814
TriFoil Imaging, Inc. Dr. Joann Zhang Tools and Technologies II Tri-resolution Visualization System for Stem Cells and Tissue Regeneration Monitoring $1,456,989
Cedars-Sinai Medical Center Professor Clive Niels Svendsen Tools and Technologies II Use of iPS cells (iPSCs) to develop novels tools for the treatment of spinal muscular atrophy. $1,933,022
University of California, Berkeley Dr. David V. Schaffer Tools and Technologies II Engineering Defined and Scaleable Systems for Dopaminergic Neuron Differentiation of hPSCs $1,340,816
Stanford University Dr. Brian K. Rutt Tools and Technologies II Development of Single Cell MRI Technology using Genetically-Encoded Iron-Based Reporters $1,833,348
Parkinson’s Institute Dr. Birgitt Schuele Tools and Technologies II Editing of Parkinson’s disease mutation in patient-derived iPSCs by zinc-finger nucleases $1,327,983
University of California, San Francisco Dr Daniel A. Lim MD, PHD Tools and Technologies II Development and preclinical testing of new devices for cell transplantation to the brain. $1,795,891
GMR Epigenetics Dr. Jifan Hu Tools and Technologies II Robust generation of induced pluripotent stem cells by a potent set of engineered factors $1,356,052
Stanford University Dr. Sarah C Heilshorn Tools and Technologies II Preparation and Delivery of Clinically Relevant Numbers of Stem Cells Using 3D Hydrogels $600,695
University of California, San Diego Dr. Lawrence S. B. Goldstein Tools and Technologies II Developing a method for rapid identification of high-quality disease specific hIPSC lines $1,686,069
University of California, Los Angeles Dr. Richard A. Gatti Tools and Technologies II Use of hiPSCs to develop lead compounds for the treatment of genetic diseases $1,833,054
Stanford University Dr. Theo D. Palmer PhD Tools and Technologies II Development of small molecule screens for autism using patient-derived iPS cells $1,797,606
University of California, Berkeley Dr. Steven M. Conolly Tools and Technologies II Magnetic Particle Imaging: A Novel Ultra-sensitive Imaging Scanner for Tracking Stem Cells In Vivo $1,311,596
University of California, San Diego Shu Chien Tools and Technologies II Development of Synthetic Microenvironments for Stem Cell Growth and Differentiation $1,706,628
University of California, Los Angeles Dr. Thomas Carmichael M.D., Ph.D. Tools and Technologies II Development of a Hydrogel Matrix for Stem Cell Growth and Neural Repair after Stroke $1,825,613
Stanford University Dr. Michele Calos Tools and Technologies II Site-specific integration of Lmx1a, FoxA2, & Otx2 to optimize dopaminergic differentiation $1,592,897
Fluidigm Corporation Dr. Marc A Unger Tools and Technologies II Development and Application of Versatile, Automated, Microfluidic Cell Culture System $1,939,236
University of California, Los Angeles Dr. Martin Gabriel Martin Tools and Technologies II Pluripotent and Somatic Stem Cell Models to Study Inherited Diarrheal Disorders $1,783,250
University of California, Los Angeles Dr. Sophie X Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $697,507
University of California, San Francisco Dr. Arturo Alvarez-Buylla Early Translational II Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy $1,564,016
University of California, Davis Dr. Mark Zern Early Translational II Liver Cell Transplantation $4,212,621
Stanford University Dr. Michele Calos Early Translational II Stem Cell Therapy for Duchenne Muscular Dystrophy $2,267,261
University of California, Irvine Dr. Brian J. Cummings Early Translational II Neural restricted, FAC-sorted, human neural stem cells to treat traumatic brain injury $1,517,767
University of California, Los Angeles Dr. Sophie X Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $1,524,947
Cedars-Sinai Medical Center Dr. Dan Gazit Early Translational II Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures $1,927,698
University of California, Los Angeles Leif Havton Early Translational II Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons $75,628
University of California, Irvine Leif A Havton Early Translational II Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons $1,527,011
City of Hope, Beckman Research Institute Dr. Yanhong Shi Ph.D. Early Translational II Developing a therapeutic candidate for Canavan disease using induced pluripotent stem cell $1,835,983
City of Hope, Beckman Research Institute Dr. David Louis DiGiusto Early Translational II Development of RNA-based approaches to stem cell gene therapy for HIV $3,097,160
University of California, Davis Dr. Roslyn Rivkah Isseroff Early Translational II Bone Marrow Mesenchymal Stem Cells to Heal Chronic Diabetic Wounds $4,629,747
University of California, Los Angeles Dr. Noriyuki Kasahara Early Translational II Stem cell-based carriers for RCR vector delivery to glioblastoma $3,340,625
Salk Institute for Biological Studies Dr. Fred H Gage Early Translational II Crosstalk: Inflammation in Parkinson’s disease (PD) in a humanized in vitro model $2,472,839
University of California, Irvine Dr. Henry John Klassen Early Translational II Human retinal progenitor cells as candidate therapy for retinitis pigmentosa $1,803,768
Children’s Hospital of Los Angeles Dr. Markus Muschen Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $850,769
University of California, San Francisco Markus Muschen Early Translational II Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication $2,756,536
Buck Institute for Age Research Dr. Xianmin Zeng Early Translational II Banking transplant ready dopaminergic neurons using a scalable process $4,983,013
iPierian, Inc. Dr. John Dimos Early Translational II New Drug Discovery for SMA using Patient-derived Induced Pluripotent Stem Cells $2,410,000
University of California, Los Angeles Prof. Bruno Peault Early Translational II Harnessing native fat-residing stem cells for bone regeneration $5,359,076
Scripps Research Institute Peter G. Schultz Early Translational II Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis $6,047,249
University of California, San Diego Professor Alysson R Muotri Early Translational II Developing a drug-screening system for Autism Spectrum Disorders using human neurons $1,376,198
University of California, Irvine Dr. Leslie M Thompson Early Translational II A hESc-based Development Candidate for Huntington’s Disease $3,955,038
University of California, San Diego Catriona Jamieson Early Translational II Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy $3,103,041
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 … 30